RxDoctor Payments Data

Adil Irani, MD

Cardiovascular Disease · Fremont, CANPI 1750540621

Payments from drug & device makers

$247in general payments, 2019–2025

Across 8 payments — averaging $30.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$125
  • Angiodynamics, Inc.$32
  • Pfizer$27
  • Atricure, Inc.$27
  • Novartis$22
  • Medtronic$14

What the payments were for

  • Food & beverage$247100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed2$125
Angiodynamics, Inc.1$32
Pfizer2$27
Atricure, Inc.1$27
Novartis1$22
Medtronic1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$247 in reported general payments places this provider in the 15th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$123,286
Medicare patients
1,073
Services billed
1,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$85,259
EntrestoSacubitril/Valsartan19$25,743
FarxigaDapagliflozin Propanediol22$21,298
JardianceEmpagliflozin20$19,466
VerquvoVericiguat12$16,162
Repatha SureclickEvolocumab15$8,123
BrilintaTicagrelor12$6,155
VascepaIcosapent Ethyl12$2,090
Losartan Potassium96$1,218
Atorvastatin Calcium120$989
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$895
Rosuvastatin Calcium33$870
Metoprolol Succinate65$775
Amlodipine Besylate78$706
Isosorbide Dinitrate21$641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$85,25971 claims
NovartisEntresto$22$25,74319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Fremont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →